(dimethylamino)(4-fluorophenyl)acetic acid | 868151-37-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (dimethylamino)(4-fluorophenyl)acetic acid
• 英文别名: 2-(dimethylazaniumyl)-2-(4-fluorophenyl)acetate
• CAS: 868151-37-5
• 化学式: C₁₀H₁₂FNO₂
• 分子量: 197.209
• InChiKey: HPWYTTSVBAFXAB-UHFFFAOYSA-N

物化性质

• 沸点：
  265.0±30.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  44.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  (dimethylamino)(4-fluorophenyl)acetic acid 、 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain

  摘要：

  Rhodesain, the major cathepsin L-like cysteine protease in the protozoan Trypanosoma brucei rhodesiense, the causative agent of African sleeping sickness, is a well-validated drug target. In this work, we used a fragment-based approach to identify inhibitors of this cysteine protease, and identified inhibitors of T. brucei. To discover inhibitors active against rhodesain and T. brucei, we screened a library of covalent fragments against rhodesain and conducted preliminary SAR studies. We envision that in vitro enzymatic assays will further expand the use of the covalent tethering method, a simple fragment-based drug discovery technique to discover covalent drug leads. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.08.074
• 作为产物：
  描述：

  4-氟苯硼酸 、 二甲胺 、 乙醛酸 以 二氯甲烷 为溶剂， 生成 (dimethylamino)(4-fluorophenyl)acetic acid
  参考文献：
  名称：

  [EN] ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS
  [FR] DERIVES D'ARYLE GLYCINAMIDE ET UTILISATION EN TANT QU'ANTAGONISTES DE NK1 ET EN TANT QU'INHIBITEURS DU RECAPTAGE DE SEROTONINE

  摘要：

  以下式(I)的化合物，其中R1和R2独立地选自烷基或烯基或杂环环以及它们所结合的N，n为0-2，Ar1为(取代)苯基，Ar1为(取代)苯基，萘基或四氢萘，进一步在说明书中定义，活体内可水解的前体和药用可接受的盐，用于治疗和药物组合物以及使用相同的方法。该化合物是神经激肽1(NK1)受体拮抗剂和/或5-羟色胺再摄取抑制剂，用于治疗抑郁症、焦虑症和其他疾病。

  公开号：

  WO2005100325A1

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF HIV<br/>[FR] COMPOSÉS POUR TRAITER LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2013006738A1

  公开（公告）日：2013-01-10

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供了如下式（I）的化合物或其盐，还提供了包含如下式（I）化合物的药物组合物，制备如下式（I）化合物的方法，用于制备如下式（I）化合物的中间体以及治疗Retroviridae病毒感染的治疗方法，包括由HIV病毒引起的感染。
• Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors
  申请人：Bernstein Peter

  公开号：US20070203139A1

  公开（公告）日：2007-08-30

  Compounds of the following Formula (I) wherein R 1 and R 2 are independently selected from alkyl or alkenyl or from a heterocyclic ring together with the N to which they are bound, n is 0-2, Ar 1 is (substituted) phenyl and Ar 1 is (substituted) phenyl, naphthyl or tetralin, further as defined in the specification, in vivo-hydrolysable precursors and pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The compounds are neurokinin 1 (NK 1 ) receptor antagonists and/or serotonin reuptake inhibitors, with medical indications for depression, anxiety disorders and other conditions.

  以下式子（I）的化合物，其中R1和R2分别选自烷基或烯基或与它们结合的N形成的杂环，n为0-2，Ar1为（取代）苯基，Ar2为（取代）苯基、萘基或四氢萘基，进一步如规范中所定义的，其在体内可水解的前体和药学上可接受的盐，用于治疗和制备药物组合物以及使用它们的治疗方法。这些化合物是神经激肽1（NK1）受体拮抗剂和/或血清素再摄取抑制剂，具有治疗抑郁症、焦虑症和其他疾病的医学适应症。
• COMPOUNDS FOR THE TREATMENT OF HIV
  申请人：Bondy Steven S.

  公开号：US20140142085A1

  公开（公告）日：2014-05-22

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供了以下式子（I）的化合物或其盐，如本文所述。本发明还提供了包括式子（I）化合物的制药组合物，制备式子（I）化合物的方法，用于制备式子I化合物的中间体以及治疗逆转录病毒感染的治疗方法，包括由HIV病毒引起的感染。
• Compounds for the treatment of HIV
  申请人：Gilead Sciences, Inc.

  公开号：US10370358B2

  公开（公告）日：2019-08-06

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供如本文所述的式(I)化合物或其盐。本发明还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺、用于制备式（I）化合物的中间体以及治疗逆转录病毒科病毒感染（包括由 HIV 病毒引起的感染）的治疗方法。
• ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS
  申请人：AstraZeneca AB

  公开号：EP1740553A1

  公开（公告）日：2007-01-10